The way we diagnose sleep apnea is this surrogate endpoint called the apnea-hypopnea index. But, sometimes, this has very ...

CHICAGO -- An investigational proximal hypoglossal nerve stimulation device helped control obstructive sleep apnea (OSA), the ...

Adults with mild to severe obstructive sleep apnea achieved lower disease severity with AD109, an oral combination drug, at ...

In patients with obstructive sleep apnea, combining supplemental oxygen with a mandibular advancement device leads to greater ...

Please provide your email address to receive an email when new articles are posted on . Several clinical and CPAP-related variables were linked to a greater risk for high residual apnea-hypopnea index ...

GLP-1 inhibitors, like tirzepatide, show promise in reducing AHI in OSA patients with obesity, as demonstrated in the SURMOUNT trials. Experts highlight the importance of integrating GLP-1s with diet ...

Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...

Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...

(HealthDay News) — Higher exposure to long-term air pollution may worsen symptoms of sleep apnea, according to a study presented at the annual congress of the European Respiratory Society, held from ...

Credit: Shutterstock. Dayvigo is an orexin receptor antagonist. The prescribing information for Dayvigo ® (lemborexant) has been updated to include clinical trial data related to the use of the ...